When living with EGFR mutation-positive metastatic non-small cell lung cancer (NSCLC)…
CYRAMZA may help you fight for what matters to you
You’re not the type to settle for average. You’re the type who pushes for more. But where individual results with CYRAMZA can vary, clinical studies have shown...
More time without disease progression
In a clinical study, CYRAMZA + erlotinib provided more time without disease progression than placebo + erlotinib for people with metastatic NSCLC with certain types of EGFR mutations.
- On average, people taking CYRAMZA + erlotinib lived 19 months without disease progression compared with 12 months for those taking placebo + erlotinib
The clinical study is still ongoing to determine if CYRAMZA + erlotinib may help you live longer compared with placebo + erlotinib.
People had tumor shrinkage
In a clinical study, tumors shrank* in 76% of people taking CYRAMZA + erlotinib compared with 75% of those taking placebo + erlotinib.
*The percentage of patients who experienced tumor shrinkage was similar between those taking CYRAMZA + erlotinib compared with those taking placebo + erlotinib. Tumor shrinkage is defined as a reduction of 30% or more in tumor size.
CYRAMZA + erlotinib was studied in a clinical trial for the initial treatment of people with metastatic NSCLC with certain EGFR mutations. Of the 449 people included in the trial, 224 people received CYRAMZA + erlotinib and 225 people received placebo + erlotinib.
The trial was designed to measure disease progression, which is the time that people lived without their cancer spreading or growing after taking treatment. The study also measured the proportion of patients who had a reduction in tumor size of 30% or more.
SELECT SAFETY INFORMATION
CYRAMZA may cause serious side effects, including:
Severe bleeding, including bleeding in the stomach or bowel, has happened with CYRAMZA. This can be life threatening. Tell your doctor right away if you have bleeding or symptoms of bleeding, including lightheadedness. If severe bleeding happens, you will have to stop receiving CYRAMZA.